ADAPTIVE BIOTECHNOLOGIES CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 1.11 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 1.11K shares, a 99.39% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 538.00 shares, a 93.47% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 701.00 shares, a 95.18% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 205.13K shares, a 71.47% decline from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 718.92K shares, a 30.23% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 1.03M shares, a 37.78% decline from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 1.66M shares, a 66.86% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 1.11K shares 10-Q · filed 2026-08-04 | 1.65K shares derived: sum of 3 quarters · filed 2026-08-04 | 2.35K shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 1.11K shares 10-Q · filed 2026-05-05 | 1.65K shares derived: sum of 2 quarters · filed 2026-05-05 | 2.35K shares derived: sum of 3 quarters · filed 2026-05-05 | 23.18K shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 538.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 1.24K shares derived: sum of 2 quarters · filed 2026-02-26 | 22.07K shares derived: sum of 3 quarters · filed 2026-02-26 | 205.13K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 701.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 21.53K shares derived: sum of 2 quarters · filed 2025-11-05 | 204.59K shares 10-Q · filed 2025-11-05 | 212.83K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 20.83K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 203.89K shares 10-Q · filed 2025-08-05 | 212.13K shares derived: sum of 3 quarters · filed 2025-08-05 | 226.66K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 183.06K shares 10-Q · filed 2025-05-01 | 191.30K shares derived: sum of 2 quarters · filed 2025-05-01 | 205.83K shares derived: sum of 3 quarters · filed 2025-05-01 | 706.23K shares derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | 8.24K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 22.77K shares derived: sum of 2 quarters · filed 2025-03-03 | 523.17K shares derived: sum of 3 quarters · filed 2025-03-03 | 718.92K shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 14.53K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 514.93K shares derived: sum of 2 quarters · filed 2024-11-07 | 710.68K shares 10-Q · filed 2024-11-07 | 740.28K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 500.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | 696.15K shares 10-Q · filed 2024-08-01 | 725.75K shares derived: sum of 3 quarters · filed 2024-08-01 | 1.22M shares derived: sum of 4 quarters · filed 2024-08-01 |
| 2024-03-31 | 195.75K shares 10-Q · filed 2024-05-07 | 225.35K shares derived: sum of 2 quarters · filed 2024-05-07 | 723.47K shares derived: sum of 3 quarters · filed 2024-05-07 | 1.10M shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 29.61K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 527.72K shares derived: sum of 2 quarters · filed 2024-02-29 | 907.07K shares derived: sum of 3 quarters · filed 2024-02-29 | 1.03M shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 498.11K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 877.46K shares derived: sum of 2 quarters · filed 2023-11-09 | 1.00M shares 10-Q · filed 2023-11-09 | 1.10M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 379.35K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | 502.67K shares 10-Q · filed 2023-08-02 | 603.65K shares derived: sum of 3 quarters · filed 2023-08-02 | 918.05K shares derived: sum of 4 quarters · filed 2023-08-02 |
| 2023-03-31 | 123.32K shares 10-Q · filed 2023-05-03 | 224.30K shares derived: sum of 2 quarters · filed 2023-05-03 | 538.70K shares derived: sum of 3 quarters · filed 2023-05-03 | 983.65K shares derived: sum of 4 quarters · filed 2023-05-03 |
| 2022-12-31 | 100.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | 415.38K shares derived: sum of 2 quarters · filed 2023-02-14 | 860.33K shares derived: sum of 3 quarters · filed 2023-02-14 | 1.66M shares 10-K · filed 2023-02-14 |
| 2022-09-30 | 314.39K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 759.35K shares derived: sum of 2 quarters · filed 2022-11-03 | 1.55M shares 10-Q · filed 2022-11-03 | 1.80M shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 444.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | 1.24M shares 10-Q · filed 2022-08-03 | 1.49M shares derived: sum of 3 quarters · filed 2022-08-03 | 1.74M shares derived: sum of 4 quarters · filed 2022-08-03 |
| 2022-03-31 | 795.63K shares 10-Q · filed 2022-05-04 | 1.04M shares derived: sum of 2 quarters · filed 2022-05-04 | 1.29M shares derived: sum of 3 quarters · filed 2022-05-04 | 1.46M shares derived: sum of 4 quarters · filed 2022-05-04 |
| 2021-12-31 | 247.93K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | 498.57K shares derived: sum of 2 quarters · filed 2022-02-15 | 663.83K shares derived: sum of 3 quarters · filed 2022-02-15 | 992.43K shares 10-K · filed 2022-02-15 |
| 2021-09-30 | 250.64K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 415.91K shares derived: sum of 2 quarters · filed 2021-11-03 | 744.50K shares 10-Q · filed 2021-11-03 | 795.57K shares derived: sum of 4 quarters · filed 2021-11-03 |
| 2021-06-30 | 165.26K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | 493.86K shares 10-Q · filed 2021-08-04 | 544.93K shares derived: sum of 3 quarters · filed 2021-08-04 | 641.31K shares derived: sum of 4 quarters · filed 2021-08-04 |
| 2021-03-31 | 328.59K shares 10-Q · filed 2021-05-05 | 379.66K shares derived: sum of 2 quarters · filed 2021-05-05 | 476.05K shares derived: sum of 3 quarters · filed 2021-05-05 | 496.02K shares derived: sum of 4 quarters · filed 2021-05-05 |
| 2020-12-31 | 51.07K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | 147.46K shares derived: sum of 2 quarters · filed 2021-02-24 | 167.43K shares derived: sum of 3 quarters · filed 2021-02-24 | 235.54K shares 10-K · filed 2021-02-24 |
| 2020-09-30 | 96.39K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | 116.36K shares derived: sum of 2 quarters · filed 2020-11-10 | 184.47K shares 10-Q · filed 2020-11-10 | 229.15K shares derived: sum of 4 quarters · filed 2020-11-10 |
| 2020-06-30 | 19.98K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | 88.08K shares 10-Q · filed 2020-08-10 | 132.77K shares derived: sum of 3 quarters · filed 2020-08-10 | |
| 2020-03-31 | 68.11K shares 10-Q · filed 2020-05-12 | 112.79K shares derived: sum of 2 quarters · filed 2020-05-12 | ||
| 2019-12-31 | 44.68K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | 412.36K shares 10-K · filed 2020-02-26 | ||
| 2019-09-30 | 367.68K shares 10-Q · filed 2019-11-12 | |||
| 2018-12-31 | 929.52K shares 10-K · filed 2020-02-26 | |||
| 2017-12-31 | 2.21M shares 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |